CRWD vs MRK: Which Is the Better Buy?
Side-by-side comparison of CrowdStrike Holdings, Inc. and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
CrowdStrike Holdings, Inc. · Technology
$259.67
-13.1% upside to fair value
Low Conviction
Grade C
High Quality
VS
Merck & Co., Inc. · Healthcare
$147.17
-4.1% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
MRK has more upside to fair value
(-4.1%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRWD |
MRK |
| Current Price |
$259.67 |
$147.17 |
| Fair Value Estimate |
$225.56 |
$141.07 |
| Upside to Fair Value |
-13.1%
|
-4.1%
|
| Market Cap |
$264.4B |
$363.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
595.7x
|
29.6x
|
| Price / Sales |
49.0x
|
5.5x
|
| Price / FCF |
167.9x
|
22.6x
|
| Revenue Growth YoY |
+25.8%
|
+5.1%
|
| Gross Margin |
75.2%
|
75.4%
|
| Operating Margin |
-2.2%
|
16.7%
|
| Return on Equity |
1.3%
|
6.6%
|
| Dividend Yield |
0% |
2.31% |
| FCF Yield |
0.6%
|
4.42%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
CrowdStrike Holdings is a cloud-native cybersecurity platform company that sells subscriptions to its Falcon platform and a growing array of cloud modules spanning endpoint protection, cloud workload security, identity protection, Next-Gen SIEM, threat intelligence, and managed services, generating revenue through a direct sales force and channel partners from its Austin, Texas headquarters with …
Merck & Co., Inc. is a global healthcare leader with two core divisions, Pharmaceuticals and Animal Health, spanning oncology, vaccines, acute hospital care, immunology, neuroscience, virology, cardiovascular and diabetes, and it employs roughly 74,000 people under CEO Robert Davis. The business quality is medium: TTM gross margin of 75.4% and TTM operating margin of 16.7% reflect a genuinely hig…
Accumulation Zones
| Metric |
CRWD |
MRK |
| Zone Low |
$169.17 |
$105.80 |
| Zone High |
$191.73 |
$119.91 |
| In Buy Zone? |
No
|
No
|